Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
96.44 USD 1.42 ( 1.49%)
Last update at 2026-11-11T21:01:00Z
VOLUME
579796
Market Cap
1350.70M
P/E
146.46

Momentum Score

…

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
93.48
Low
96.44
High
52 Week Price Range
13.56
Low
22.09
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
95.02
Dividend Yield
-
Revenue TTM
301.77M
Revenue Per Share
4.29
Gross Profit TTM
173.21M
Debt / Equity
0.03
ROE
2.11%
Net Debt
-95.70M
ROCE
1.59%
Diluted EPS TTM
0.13

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 11.03M -156.54M -156.23M -163.91M -103.44M
Net income 183.36M -157.92M -161.38M -161.87M -103.23M
Selling general administrative 97.95M 85.95M 45.32M 34.96M 21.56M
Gross profit 173.21M 29.44M - - 0.00M
Reconciled depreciation 2.40M 2.35M 2.40M 2.07M 0.29M
Ebit 7.37M -158.99M -159.77M -172.03M -108.45M
Ebitda 9.77M -156.64M -157.36M -169.96M -108.16M
Depreciation and amortization 2.40M 2.35M 2.40M 2.07M 0.29M
Non operating income net other 1.25M 0.10M 1.13M 6.05M 4.72M
Operating income 7.37M -156.64M -157.36M -169.96M -108.16M
Other operating expenses 210.41M 195.18M 157.36M 169.96M 108.16M
Interest expense 1.25M 2.45M 3.54M 8.12M 0.00M
Tax provision -172.34M 1.39M 5.15M -2.05M -0.21M
Interest income 1.25M 0.10M 1.13M 6.05M 4.72M
Net interest income 1.25M 0.10M 1.13M 6.05M 4.72M
Non recurring - 0.83M - - -
Income tax expense -172.34M 1.39M 5.15M -2.05M -0.21M
Total revenue 220.18M 38.54M 0.00M 0.00M 0.00M
Total operating expenses 163.44M 186.08M 157.36M 169.96M 108.16M
Cost of revenue 46.97M 9.10M - - 0.00M
Total other income expense net 3.65M 0.10M 1.13M 6.05M 4.72M
Net income from continuing ops 183.36M -157.92M -161.38M -161.87M -103.23M
Net income applicable to common shares 183.36M -157.92M -161.38M -161.87M -103.23M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 526.32M 459.67M 232.80M 349.46M 254.53M
Intangible assets 17.25M 18.25M 19.25M - -
Other current assets 17.54M 10.54M 6.58M 9.56M 8.25M
Total liab 87.48M 63.52M 47.76M 37.53M 29.11M
Total stockholder equity 438.84M -492.03M -675.40M -517.47M -356.09M
Other current liab 52.86M 23.87M 1.54M 0.04M 0.03M
Common stock 0.02M 0.02M 0.02M 0.02M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.01M
Retained earnings -477.95M -492.03M -675.40M -517.47M -356.09M
Other liab - 13.84M 0.27M 0.81M 0.33M
Other assets 0.00M 191.32M 8.72M 12.16M 4.58M
Cash 107.95M 122.72M 122.47M 114.04M 46.93M
Total current liabilities 63.67M 47.07M 44.82M 31.85M 27.83M
Current deferred revenue 0.31M 12.00M 38.03M 29.20M 20.41M
Net debt -95.70M -116.80M -116.42M -107.05M -44.28M
Short term debt 2.25M 3.30M 3.38M 2.11M 1.70M
Short long term debt total 12.26M 5.92M 6.05M 6.99M 2.65M
Other stockholder equity 916.76M -0.06M 0.05M 0.02M -0.05M
Property plant equipment - 1.66M 2.83M 4.05M 8.32M
Total current assets 276.30M 243.06M 196.45M 333.25M 241.63M
Net tangible assets - 377.90M 194.55M 311.94M 225.42M
Short term investments 98.42M 67.89M 59.73M 209.44M 186.45M
Net receivables 21.27M 20.32M 3.98M - -
Inventory 31.12M 21.60M 3.67M - -
Accounts payable 8.25M 7.90M 1.87M 0.50M 5.69M
Accumulated other comprehensive income 0.01M 0.04M -0.07M -0.03M 0.03M
Common stock total equity - 0.02M 0.02M 0.02M 0.01M
Retained earnings total equity - -492.03M -675.40M -517.47M -356.09M
Non currrent assets other 0.83M 5.82M 8.72M 5.59M 0.21M
Non current assets total 250.02M 216.61M 36.35M 16.21M 12.91M
Capital lease obligations 12.26M 5.92M 6.05M 6.99M 2.65M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -8.06M 149.05M -23.16M 52.42M -233.91M
Change to liabilities 15.89M 11.17M 4.31M 0.26M 18.12M
Total cashflows from investing activities -8.08M 128.63M -23.44M 49.21M -239.20M
Total cash from financing activities 2.52M 5.88M 227.09M 84.11M 346.74M
Change to operating activities -6.35M 6.91M 0.65M -12.32M 9.51M
Net income 183.36M -157.92M -161.38M -161.87M -103.23M
Change in cash 0.24M 8.22M 67.11M -25.05M 26.53M
Begin period cash flow 122.47M 114.25M 47.14M 72.19M 45.66M
End period cash flow 122.72M 122.47M 114.25M 47.14M 72.19M
Total cash from operating activities 5.81M -126.30M -136.53M -158.37M -81.01M
Issuance of capital stock 3.42M 0.00M 221.67M 83.11M 350.02M
Depreciation 2.40M 2.35M 2.40M 2.07M 0.29M
Other cashflows from investing activities 0.09M -20.00M - 52.42M -233.91M
Change to inventory -17.92M -3.67M -3.67M -3.67M -3.67M
Change to account receivables -8.68M -3.91M -3.91M -3.91M -3.91M
Sale purchase of stock -0.90M 5.88M 6.55M 84.22M 350.39M
Other cashflows from financing activities -8.08M 128.63M -1.14M 1.00M 187.54M
Change to netincome -160.34M 25.29M 25.24M 11.95M 4.79M
Capital expenditures 0.10M 20.41M 0.28M 3.20M 5.29M
Change receivables -8.68M -3.91M - - -
Cash flows other operating -8.83M -0.27M -7.22M -7.27M 0.44M
Cash and cash equivalents changes 0.24M 8.22M 67.11M -25.05M 26.53M
Change in working capital -22.57M 0.69M -4.32M -17.02M 18.33M
Stock based compensation 25.12M 25.17M 20.88M 15.08M 5.70M
Other non cash items 2.99M 3.40M 1.52M 6.53M -1.12M
Free cash flow 5.70M -146.71M -136.81M -161.57M -86.30M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KNSA
Kiniksa Pharmaceuticals Ltd		 1.42
1.49%		 96.44 146.46 - 4.52 2.78 3.80 -44.93
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Clarendon House, Hamilton, Bermuda, HM 11

448 08189 6257

https://www.kiniksa.com

297

Name Title Year Born
Mr. Sanj K. Patel CEO & Chairman 1970
Dr. John F. Paolini Sr. VP & Chief Medical Officer 1965
Mr. Mark Ragosa C.F.A. Sr. VP & CFO 1975
Mr. Eben Tessari Sr. VP & COO 1982
Mr. Michael R. Megna CPA Chief Accounting Officer & Group VP of Fin. 1971
Ms. Mei Jang Sr. VP of Technical Operations NA
Rachel Frank Associate Director of Investor Relations NA
Mr. Chad Morin Sr. VP & Chief Compliance Officer NA
Ms. Madelyn Zeylikman SVP, Gen. Counsel & Sec. NA
Ms. Melissa Manno Sr. VP & Chief HR Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…